Please login to the form below

Not currently logged in
Email:
Password:

Merck enters Alzheimer's partnership

Merck has entered into a $289m research partnership with Alectos Therapeutics

Merck has entered into a research partnership with Alectos Therapeutics focused on compounds that modulate the enzyme -linked N-acetylglucosaminidase (O-GlcNAcase).

The deal, which is valued at $289m, gives Merck exclusive global rights to research, develop and commercialise compounds that modulate the target in return for an upfront payment, milestones, royalties, and research funding for Alectos' existing portfolio of compounds targeting Alzheimer's disease. 

The agreement calls for Alectos and Merck to partner on discovery and preclinical development, with Merck taking over full responsibility for clinical development. The companies may also develop products that modulate the enzyme as treatments for other neurological diseases.

Alectos was founded by researchers from Canada's Simon Frasier University.

11th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics